Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents Big Molecule WatchOn March 20, 2026, Accord BioPharma, Inc.RegulatoryImmunology & InflammationRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) Big Molecule Watch On March 20, 2026, Accord BioPharma, Inc. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Otsuka picks up PTSD drug with $700M Transcend buyNext: S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026